Imaging of multiple myeloma: Current concepts  

作　　者：Thorsten Derlin Peter Bannas 

机构地区：[1]Department of Diagnostic and Interventional Radiology,University Medical Center HamburgEppendorf,DE-20246 Hamburg,Germany

出　　处：《World Journal of Orthopedics》2014年第3期272-282,共11页世界骨科杂志（英文版）

摘　　要：Medical imaging is of crucial importance for diagnosis and initial staging as well as for differentiation of multiple myeloma(MM)from other monoclonal plasma cell diseases.Conventional radiography represents the reference standard for diagnosis of MM due to its wide availability and low costs despite its known limitations such as low sensitivity,limited specificity and its inability to detect extraosseous lesions.Besides conventional radiography,newer cross-sectional imaging modalities such as whole-body low-dose computed tomography(CT),whole-body magnetic resonance imaging(MRI)and18F-fluorodeoxyglucose(FDG)positron emission tomography(PET)/CT are available for the diagnosis of osseous and extraosseous manifestations of MM.Whole-body low-dose CT is used increasingly,replacing conventional radiography at selected centers,due to its higher sensitivity for the detection of osseous lesions and its ability to diagnose extraosseous lesions.The highest sensitivity for both detection of bone marrow disease and extraosseous lesions can be achieved with whole-body MRI and18F-FDG PET/CT.According to current evidence,MRI is the most sensitive method for initial staging while18F-FDG PET/CT allows monitoring of treatment of MM.There is an evolving role for assessment of treatment response using newer MR imagingtechniques.Future studies are needed to further define the exact role of the different imaging modalities for individual risk stratification and therapy monitoring.Medical imaging is of crucial importance for diagnosis and initial staging as well as for differentiation of multiple myeloma(MM) from other monoclonal plasma cell diseases. Conventional radiography represents the reference standard for diagnosis of MM due to its wide availability and low costs despite its known limitations such as low sensitivity, limited specificity and its inability to detect extraosseous lesions. Besides conventional radiography, newer cross-sectional imaging modalities such as whole-body low-dose computed tomography(CT), whole-body magnetic resonance imaging(MRI)and 18F-fluorodeoxyglucose(FDG) positron emission tomography(PET)/CT are available for the diagnosis of osseous and extraosseous manifestations of MM.Whole-body low-dose CT is used increasingly, replacing conventional radiography at selected centers, due to its higher sensitivity for the detection of osseous lesions and its ability to diagnose extraosseous lesions. The highest sensitivity for both detection of bone marrow disease and extraosseous lesions can be achieved with whole-body MRI and 18F-FDG PET/CT. According to current evidence, MRI is the most sensitive method for initial staging while 18F-FDG PET/CT allows monitoring of treatment of MM. There is an evolving role for assessment of treatment response using newer MR imagingtechniques. Future studies are needed to further define the exact role of the different imaging modalities for individual risk stratification and therapy monitoring.

关 键 词：Multiple MYELOMA PLASMOCYTOMA X-Ray Magnetic resonance IMAGING DIFFUSION-WEIGHTED IMAGING Positron emission tomography-computed TOMOGRAPHY IMAGING 

分 类 号：R733.3[医药卫生—肿瘤] R730.44[医药卫生—临床医学]